HOME ABOUT CONTACT AVAILABLE ISSUES SUBSCRIBE MEDIA & ADS CONFERENCE CALENDAR
LATEST UPDATES » Vol 22, No 02, February 2018 – Searching for the fountain of youth       » Chinese researchers cloned monkeys       » National Science and Technology Prizes       » Highlights from the State Natural Science Award       » Highlights from the State Technological Invention Award      
BIOBOARD - AUSTRALIA
Fellowship supports search for new disease treatments

La Trobe University and leading Australian biotech company AdAlta have received new funding to identify and develop potential treatments for a range of human diseases using the company’s novel class of drugs, known as i-bodies.

La Trobe University’s Dr Chris Hosking has been awarded a Science and Industry Endowment Fund (SIEF) Business Fellowship worth $427,000 ($210,000 from the CSIRO), further strengthening the collaboration between La Trobe University and AdAlta.

The SIEF Business Fellowship Program aims to build deeper connections and collaborations between researchers and industry, accelerate the adoption of new ideas and technology, while also helping to grow into larger and more profitable organisations.

Furthermore, the program provides practical industry experience for early career researchers.

The SIEF Fellowship grant will support Dr Hosking’s work with AdAlta’s Chief Scientific Officer, Professor Mick Foley, at the La Trobe Institute for Molecular Science.

“Under the SIEF grant we will screen the i-body library to identify and develop new i-body candidates against difficult to access drug targets, such as complex signalling proteins called GPCRs,” Professor Foley said.

“Chris is an excellent candidate for the Fellowship because he has extensive experience working with phage displays and screening libraries. Chris brings significant expertise to the AdAlta team.”

La Trobe Pro Vice Chancellor Industry and Engagement, Dr Daniel Grant, congratulated Dr Hosking.

“La Trobe recognises the importance of engaging with, and building strong partnerships with, innovative companies,” Dr Grant said. “We have had a longstanding and productive relationship with AdAlta and this Fellowship is a great outcome for both parties.”

I-bodies are a promising, novel class of drugs that offer a new and more effective approach to treatment of a wide range of human diseases.

AdAlta pioneered a technology that mimics the shape and stability of a crucial antigen-binding domain, which was discovered initially in sharks and then developed as a human protein.

Source: La Trobe University

Click here for the complete issue.

NEWS CRUNCH  
news EmTech Asia explores future of life, humanity and economy
news Biology of Ageing II - Impactful Interventions
news Separation of conjoined twins presents surgical and ethical challenges for MassGeneral Hospital for Children staff
PR NEWSWIRE  
Asia Pacific Biotech News
EDITORS' CHOICE  

Lady Ganga: Nilza'S Story
COLUMNS  
Subscribe to APBN E-Newsletter
Find us under 'Others' option to receive APBN e-newsletters thrice a month!

APBN Editorial Calendar 2018
January:
Obesity / Outlook for 2018
February:
Searching for the fountain of youth
March:
Nutrition / Women in Science
April:
Digestive health / Intellectual property
May:
Asthma / Dental health
June:
Oncology / Biotech landscape in APAC
July:
Water management / Vaccination
August:
Regenerative medicine / Biotech start ups
September:
Digital healthcare / 3D printing
October:
Bones / Breast cancer
November:
Liver health / Top science research nations & institutions
December:
AIDS / Breakthrough of the year/Emerging trends
Editorial calendar is subjected to changes.
MAGAZINE TAGS
About Us
Events
Available issues
Editorial Board
Letters to Editor
Instructions to Authors
Advertise with Us
CONTACT
World Scientific Publishing Co. Pte. Ltd.
5 Toh Tuck Link, Singapore 596224
Tel: 65-6466-5775
Fax: 65-6467-7667
» For Editorial Enquiries:
   biotech_edit@wspc.com or Ms Lim Guan Yu
» For Subscriptions, Advertisements &
   Media Partnerships Enquiries:
   biotech_ad@wspc.com
Copyright© 2018 World Scientific Publishing Co Pte Ltd  •  Privacy Policy